^
Association details:
| Biomarker: | EGFR L858R + TP53 wild-type |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug Class: | EGFR inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prognostic and predictive effects of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs
Published date:
11/28/2023
Excerpt:
We retrospectively analyzed 236 patients and tested for TP53-and EGFR-mutant status in metastasis LUAD patients who had received first-line EGFR-tyrosine kinase inhibitors (TKIs) treatment….Subgroup analysis revealed longer median PFS and OS in TP53 wildtype group compared to the TP53 mutant group in L858R patients and not significant in EGFR Exon 19 deletion patients.
DOI:
10.3389/fonc.2023.1288468
